Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17142474 | 0.94 | HTR1A (0.48) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL3096566 | 0.89 | DPP7 (0.46) | HTR1AHRH2HRH1HRH3DPP7 | |
| SCHEMBL31719354 | 0.89 | DPP7 (0.46) | HTR1AHRH2HRH1HRH3DPP7 | |
| SCHEMBL3096581 | 0.89 | DPP7 (0.46) | HTR1AHRH2HRH1HRH3DPP7 | |
| SCHEMBL721962 | 0.86 | ALDH1A1 (0.47) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL17148081 | 0.86 | ALDH1A1 (0.47) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL17142633 | 0.86 | ALDH1A1 (0.47) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL8296862 | 0.83 | HTR1A (0.48) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL12280022 | 0.82 | PDCD1 (0.44) | HTR1AHRH2HRH1HRH3DPP7 | |
| SCHEMBL2674136 | 0.82 | PDCD1 (0.44) | HTR1AHRH2HRH1HRH3DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790902-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080300249-A1 | tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents | PFIZER, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7405218-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1616386-A | Intermediate for preparing isothiazole derivatives | PFIZER PROD INC (US) | 2005-05-18 | — | — | CN | disclosed |
| CN-1172918-C | Isothiazole derivatives as anticancer agents | �Ʒ� | 2004-10-27 | — | — | CN | disclosed |
| EP-1084114-B1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6548526-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | disclosed |
| CN-1303380-A | Isothiazole derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-07-11 | — | — | CN | disclosed |
| US-6235764-B1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | HTR1A 3215/4885HRH2 2244/4885HRH1 2223/4885 |
| US-20080300249-A1 | tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents | CDKN1A, TK1, CDK1 | HTR1A 2254/4885HRH2 1332/4885HRH1 1248/4885 |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | HTR1A 3215/4885HRH2 2244/4885HRH1 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.